Entrada Therapeutics (TRDA) EBT Margin (2023 - 2026)

Entrada Therapeutics' EBT Margin history runs 4 years deep, the most recent figure standing at 4534.74% for Q1 2026.

• In Q1 2026, EBT Margin fell 445035.0% year-over-year to 4534.74%; the TTM figure through Mar 2026 stood at 2878.29% (down 289211.0% YoY), while the FY2025 annual figure was 561.84%, down 59338.0% from the prior year.
• EBT Margin for Q1 2026 stood at 4534.74%, down from 3007.85% in the prior quarter.
• The five-year high for EBT Margin was 61.03% in Q2 2024, with the low at 4534.74% in Q1 2026.
• The 4-year median for EBT Margin is 66.49% (2023), against an average of 962.85%.
• The sharpest annual moves came in 2024 and 2026: EBT Margin soared 12752 bps in 2024, then slumped 445035 bps in 2026.
• Entrada Therapeutics' EBT Margin stood at 21.98% in 2023, then tumbled by 109 bps to 1.98% in 2024, then plunged by 152116 bps to 3007.85% in 2025, then sank by 51 bps to 4534.74% in 2026.
• Business Quant data shows TRDA's EBT Margin at 4534.74% in Q1 2026, 3007.85% in Q4 2025, and 2693.93% in Q3 2025.